anti LILRB2 CAR-T cells

Anti-LILRB2 CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target the Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2), also known as ILT4 or CD85d. LILRB2 is an inhibitory receptor primarily expressed on myeloid cells, including myeloid-derived suppressor cells (MDSCs) and certain leukemic blasts in acute myeloid leukemia (AML), where it plays a role in immune evasion and the maintenance of an immunosuppressive tumor microenvironment. By engineering autologous T cells to express a CAR specific for LILRB2, the therapy aims to selectively identify and eliminate LILRB2-expressing malignant cells. This approach is currently being evaluated in Phase 1 clinical trials by The Affiliated Hospital of Xuzhou Medical University for the treatment of patients with relapsed or refractory AML who are not candidates for allogeneic stem cell transplantation.

Other names

anti LILRB2 CAR-T cellsLILRB2-targeted CAR-T cellsLILRB-2-targeted CAR-T cellsLILRB 2-targeted CAR-T cellsanti-LILRB2 CAR-Tanti-LILRB-2 CAR-Tanti-LILRB 2 CAR-T